May 28, 2020: Anal lesion recurrence among women with HIV; non-alcoholic fatty liver disease frequency in lean patients; long-term efficacy for a smoking cessation intervention; non-lymphoid cancers following lymphoid malignancy.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
VOCAL-NY has kept its doors open through the COVID-19 pandemic to serve people who use drugs and may be living with hepatitis C, but how it provides services has changed.
March 5, 2020: How U=U reduces more than HIV transmission; "other" HPV strain risks post-vaccination; vitamin E for nonalcoholic steatohepatitis; HCV therapy and increased cardiovascular risk.
Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.